Multiple Myeloma Clinical Trials

Find clinical trials for multiple myeloma. Search for multiple myeloma clinical trials in different cities and states across the United States.

Filter

Filter results

Results: 299

Daratumumab vs. DaratumumabFixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults With Newly Diagnosed Multiple Myeloma

Recruiting

PHASE3

Sponsor:

Canadian Cancer Trials Group

Location:

Kelowna, Vancouver, Winnipeg, Monctonshow 16 more

Code:

NCT06182774

Conditions

Multiple Myeloma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Daratumumab

Lenalidomide

Dexamethasone

Selinexor, Carfilzomib, DexamethasoneSelinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Recruiting

PHASE1

Sponsor:

University of Chicago

Location:

Scottsdale AZ, Chicago IL, Ann Arbor MI, Detroit MIshow 1 more

Code:

NCT02199665

Conditions

Refractory Multiple Myeloma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

selinexor

carfilzomib

dexamethasone

Darzalex FasproDarzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

Recruiting

EARLY_PHASE1

Sponsor:

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Location:

Baltimore MD

Code:

NCT06398457

Conditions

Hematologic Malignancy

Bone Marrow Transplant Rejection

Acute Myeloid Leukemia (AML)

Myelodysplastic Syndromes (MDS)

Acute Lymphoblastic Leukemia (ALL), Adult

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Darzalex Faspro (Daratumumab and hyaluronidase-fihj)

JH-DSA Semi-Quant Screen and Response Score

CFT7455Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

Recruiting

PHASE1

PHASE2

Sponsor:

C4 Therapeutics, Inc.

Location:

Phoenix AZ, San Francisco CA, Denver CO, Jacksonville FLshow 7 more

Code:

NCT04756726

Conditions

Multiple Myeloma

Lymphoma, Non-Hodgkin's

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

cemsidomide

Dexamethasone Oral

Iberdomide, Bortezomib, Dexamethasone, IsatuximabStudy of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients

Recruiting

PHASE2

Sponsor:

Canadian Myeloma Research Group

Location:

London, Toronto

Code:

NCT05272826

Conditions

Multiple Myeloma

Eligibility Criteria

Sex: All

Age: 65+

Healthy Volunteers: Not accepted

Interventions

Iberdomide

Bortezomib

Dexamethasone

Isatuximab

Prehabilitation ExercisePrehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Recruiting

Sponsor:

Dana-Farber Cancer Institute

Location:

Boston MA

Code:

NCT05706766

Conditions

Multiple Myeloma

Stem Cell Transplant Complications

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

PARE

Waitlist Control Group

Geriatric AssessmentGeriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study

Recruiting

PHASE2

Sponsor:

City of Hope Medical Center

Location:

Duarte CA

Code:

NCT06052826

Conditions

B-Cell Non-Hodgkin Lymphoma

Multiple Myeloma

Eligibility Criteria

Sex: All

Age: 60+

Healthy Volunteers: Not accepted

Interventions

Best Practice

Cognitive Intervention

Comprehensive Geriatric Assessment

Nutritional Intervention

Physical Therapy

Dabrafenib & TrametinibA Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma

Recruiting

PHASE1

Sponsor:

Massachusetts General Hospital

Location:

Boston MA, Detroit MI

Code:

NCT03091257

Conditions

Multiple Myeloma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Dabrafenib

Trametinib

Elranatamab & Anti-Cancer TreatmentsMagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

Recruiting

PHASE2

Sponsor:

Pfizer

Location:

Gilbert AZ, Little Rock AR, Beverly Hills CA, Encino CAshow 15 more

Code:

NCT05090566

Conditions

Multiple Myeloma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Elranatamab + Nirogacestat

Elranatamab + lenalidomide + dexamethasone

Arlocabtagene AutoleucelStudy of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

Recruiting

PHASE2

Sponsor:

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Location:

Birmingham AL, Gilbert AZ, Little Rock AR, Los Angeles CAshow 34 more

Code:

NCT06297226

Conditions

Multiple Myeloma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Arlocabtagene Autoleucel (BMS-986393)